The Federal Trade Commission (FTC) on Friday sued the three largest pharmacy benefit managers (PBMs) for engaging in alleged anticompetitive practices that boosted profits while

The Federal Trade Commission sued on Friday the three largest pharmaceutical intermediaries charged with negotiating drug prices on behalf of insurers, claiming they are illegally maximizing profits by steering patients to high-cost insulin products.

The Big Three handle at least 80% of the country’s insulin prescriptions. The price of insulin has exponentially increased in recent years. Now, the Federal Trade Commission (FTC) is suing three companies over allegedly inflating the cost of the drug at the expense of Americans who rely on it.